Gromek Smolen, PHD, joined Foghorn Therapeutics in 2023 as VP of Biology. He brings more than 20 years of experience in industry and academia, with deep expertise in both oncology and immuno-oncology. Prior to joining Foghorn, Gromek led the oncology portfolio at Celsius Therapeutics, which included target identification/validation, multiple drug discovery programs, and clinical partnerships. Before Celsius, Gromek was at Agios Pharmaceuticals, where he led the cancer exploratory portfolio of target identification and validation projects. He also shaped Agios’ pipeline of targets in metabolic immuno-oncology and rare genetic diseases. Gromek obtained his PhD from Johns Hopkins University and completed his postdoctoral training in the lab of Dr. Daniel Haber at Massachusetts General Hospital/Harvard Medical School.